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ABSTRACT
Objectives To determine the burden of comorbidities
in patients with gout at diagnosis and the risk of
developing new comorbidities post diagnosis.
Methods There were 39 111 patients with incident gout
and 39 111 matched controls identiﬁed from the UK
Clinical Practice Research Data-link. The risk of comorbidity
before (ORs) and after the diagnosis of gout (HRs) were
estimated, adjusted for age, sex, diagnosis year, body mass
index, smoking and alcohol consumption.
Results Gout was associated with adjusted ORs (95%
CIs) of 1.39 (1.34 to 1.45), 1.89 (1.76 to 2.03) and 2.51
(2.19 to 2.86) for the Charlson index of 1–2, 3–4 and ≥5,
respectively. Cardiovascular and genitourinary diseases, in
addition to hyperlipidaemia, hypothyroidism, anaemia,
psoriasis, chronic pulmonary diseases, osteoarthritis and
depression, were associated with a higher risk for gout.
Gout was also associated with an adjusted HR (95% CI) of
1.41 (1.34 to 1.48) for having a Charlson index ≥1.
Median time to ﬁrst comorbidity was 43 months in cases
and 111 months in controls. Risks for incident comorbidity
were higher in cardiovascular, genitourinary, metabolic/
endocrine and musculoskeletal diseases, in addition to liver
diseases, hemiplegia, depression, anaemia and psoriasis in
patients with gout. After additionally adjusting for all
comorbidities at diagnosis, gout was associated with a HR
(95% CI) for all-cause mortality of 1.13 (1.08 to 1.18;
p<0.001).
Conclusions The majority of patients with gout have
worse pre-existing health status at diagnosis and the risk of
incident comorbidity continues to rise following diagnosis.
The range of associated comorbidities is broader than
previously recognised and merits further evaluation.
INTRODUCTION
Gout is the most common inﬂammatory arthritis
worldwide with a recent estimated prevalence of
2.49% in the UK.1 Initial presentation is usually with
acute arthritis but chronic joint damage, subcutane-
ous tophi and periarticular inﬂammation are other
common manifestations.2 Since gout results from
chronic hyperuricaemia and the deposition of urate
crystals, urate-lowering treatment (ULT) capable of
preventing crystal formation and dissolving existing
crystal deposits may potentially ‘cure’ gout.3 Gout is
also associated with comorbidities that may impair
well-being and reduce longevity.4–6 It is generally
accepted that gout is highly associated with the fea-
tures of metabolic syndrome,7 nephrolithiasis8 9 and
chronic renal impairment.10 However, suggested
associations with other cardiovascular disease6 11–14
is controversial,15 and there is only limited evidence
for possible associations with cancer,16 17 hypothy-
roidism18 19 and anaemia.20
Current clinical guidelines and recommendations
endorsed by the European League against
Rheumatism,21 American College of Rheumatology22
and British Society for Rheumatology/British Health
Professionals in Rheumatology23 agree on the import-
ance of comorbidity on gout management but only
discuss diseases that are recognised to be pathophysio-
logically related to gout. In addition, ULT is generally
recommended only for patients with high urate load
or with comorbidities such as poor kidney function.
Although a focus on comorbidities that are causally
related to or are seen as complications of gout is
understandable, many patients with gout are ‘compli-
cated’ by multiple comorbidities that may or may not
be related directly to gout and management decisions
in such cases are often difﬁcult since recommenda-
tions and guidelines give no speciﬁc guidance in these
scenarios.
Although comorbidity is considered to be epi-
demic in gout24–26 previous studies have only
included limited categories of comorbidities. In
addition, the timing of comorbidity occurrence
relative to gout diagnosis has not been addressed.
Therefore, using data representative of the general
population of UK from the Clinical Practice
Research Data-link (CPRD), this study aimed to
examine the burden of comorbidity at the time of
ﬁrst diagnosis of gout compared with matched con-
trols. We further followed patients with incident
gout and their matched controls after diagnosis to
compare their subsequent accumulation of
comorbidities and all-cause mortality.
METHODS
This was a case-control study using retrospective
data (prior to diagnosis) and subsequent follow-up
data (after diagnosis) within the CPRD. We
hypothesised that gout has a higher burden of
comorbidity at the time of ﬁrst diagnosis and that
the risk of comorbidity would continue to rise after
the diagnosis of the disease. The study was
approved by the Independent Scientiﬁc Advisory
Committee for Medicines and Healthcare Products
Regulatory Agency (MHRA) Database Research
(protocol 11-021R).
Data source
The CPRD is a database containing prospectively
collected medical records of research standard from
around 12 million individuals in the UK. The data-
base has been described previously27 and has been
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validated for many diagnoses, including gout and comorbid con-
ditions under scrutiny in this study.28–32 The database contains
comprehensive information on patient demographics, lifestyle
factors, medical diagnoses, results of investigations and examina-
tions and prescribed medications. The CPRD is also linked to
additional data sources including secondary care, Ofﬁce for
National Statistics cause of death data and information from
speciﬁc disease registries.
Deﬁnition of incident gout
We used Read codes (a standard clinical terminology system
used in general practice in the UK originally developed by Dr
James Read) to identify patients with incident gout from the
CPRD between 1997 and 2005. To be eligible as a patient with
incident gout, participants had to have no evidence of gout and
no prescription for ULT prior to the time of diagnosis (index
date) and to have at least a 3-year continuous registration prior
to the index date.33 The case deﬁnition was based on physician-
diagnosis using 18 Read codes indicative of incident gout.1 The
diagnosis of gout in the CPRD has been validated previously by
a review of medical records of 10 patients with conﬁrmed and
28 patients with probable gout showing that 10 out of 10 con-
ﬁrmed cases and 24 out of 28 probable cases were true gout
(overall ascertainment rate 90%).32
Selection of controls
From CPRD participants who had an active registration from
1997 to 2005, we identiﬁed at random one control per case
who had no record of gout and no prescriptions of ULT in the
CPRD. Control patients were frequency-matched in a 1:1 ratio
to patients with incident gout by year of birth (±2 years),
gender, general practice and year of ﬁrst continuous registration
(±2 years) at this CPRD practice. The same index date was
assigned to each of the matched controls. As with patients with
incident gout the matched controls had at least 3 years of regis-
tration prior to the index date.
Study period
We deﬁned three periods to assess comorbidity: (A) the 10 years
prior to diagnosis; (B) the 1 year prior to diagnosis; and (C)
from diagnosis to the earliest date of occurrence of comorbidity,
death, transfer out or end of study (31 December 2013), which-
ever came ﬁrst. Cumulative probability of comorbidity was esti-
mated at the time of diagnosis (index date) as well as 1 year, 2
years, 5 years and 10 years following diagnosis.
Comorbidity of interest and mortality
We deﬁned gout as the index disease in this study and used
Feinstein’s deﬁnition for comorbidity, speciﬁcally: “Any distinct
additional entity that has existed or may occur during the clin-
ical course of a patient who has the index disease under
study.”34 General health status was measured by the Charlson
comorbidity index. The index summarises 17 diagnostic cat-
egories (myocardial infarction, congestive heart failure, periph-
eral vascular disease, cerebrovascular disease, dementia, chronic
pulmonary disease, rheumatological disease, peptic ulcer
disease, mild liver disease, moderate or severe liver disease, dia-
betes mellitus (DM), DM with chronic complications, renal dis-
eases, any malignancy (including leukaemia and lymphoma),
metastatic solid tumour and HIV infection) to represent one’s
health status and has been a useful predictor for mortality.35
Deyo et al36 produced a validated version for use with the
International Classiﬁcation of Diseases, Ninth Revision (ICD-9)
based database, which was the basis of the validated Read code
version.37 We calculated the Charlson score for each study
person at baseline by adding scores assigned to each speciﬁc
diagnosis. In addition, we also incorporated other comorbidities
potentially associated with gout, including anaemia, cardiac
arrhythmias, depression, hypertension, hypothyroidism, mul-
tiple sclerosis, neurological diseases, osteoarthritis, psoriasis,
psychosis, urolithiasis and valvular heart disease (please refer to
supplement for the rationale in selection of these comorbid-
ities). All comorbidities were further categorised into eight cat-
egories according to systems. The deﬁnitions of these conditions
were also based on physician diagnoses recorded as Read codes.
We identiﬁed patients with these comorbidities from records
within each of the three study periods as stated above. The
Charlson index at diagnosis was based on results from the
10-year period. We categorised Charlson index as (1) 0, 1–2, 3–
4 and ≥5 scores and (2) dichotomised it as 0 and ≥1 score.
Mortality was based on the recording in the main database. We
undertook a validation study and found the sensitivity, speciﬁ-
city, positive predictive value and negative predictive value of a
CPRD recorded death were 0.99, 0.99, 0.93 and 1.00, respect-
ively, suggesting that the recording of death in the CPRD is gen-
erally consistent with death registration (details in online
supplement and table S1).
Statistical analysis
The prevalence of a speciﬁc comorbidity was calculated using
the number of people ever diagnosed with a given comorbidity
during the past 10-year period or 1-year period before the
index date as the numerator and the number of patients with
incident gout or matched controls as denominators. ORs and
95% CIs were used to estimate the association between gout
and each coexisting medical condition. Conditional logistic
regression was used to adjust for age, gender, index year, body
mass index (BMI) category, smoking status and alcohol con-
sumption. Missing data for BMI, smoking and alcohol status
were coded as ‘unknown’. Kaplan-Meier plots were used to esti-
mate the cumulative probability of each comorbidity and all-
cause mortality in people with incident gout and those without.
For calculation of cumulative probabilities, the ﬁrst percentage
(at baseline), indicates the percentage of people with a diagnosis
before the index date. Only people at risk for a given comorbid-
ity (not having such comorbidity at index date) were considered
to estimate HRs of a speciﬁc comorbidity. HRs with 95% CIs
were calculated for a Charlson index ≥1, for each comorbidity
separately and all-cause mortality using a Cox proportional
hazards model. The HRs were adjusted by age, gender, index
year, BMI categories, smoking status and alcohol consumption.
For all-cause mortality we also adjusted for all categories of
comorbidities at baseline. All statistical analyses were performed
using SAS statistical software, V.9.3.
RESULTS
We identiﬁed 39 111 patients with incident gout during 1997 to
2005 with a mean age of 62.2±15.1 years and 72.49% being
men. The median observation periods (interquartile range; IQR)
before and after index date were 15 (9–27) and 9 (5–11) years,
respectively. They were 1:1 matched to 39 111 controls with
the same age and sex structure and observation periods before
and after index date (table 1). The odds of gout increased sig-
niﬁcantly with BMI, alcohol consumption and smoking.
Retrospective observation
At the time of index date, the proportion of people having at
least one comorbidity listed in the Charlson index was
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signiﬁcantly higher in patients with incident gout (32.25%) than
in controls (27.97%; p<0.001). In an adjusted logistic regression
model in the 10-year period before the index date, ORs (95%
CIs) were 1.39 (1.34 to 1.45), 1.89 (1.76 to 2.03) and 2.51 (2.19
to 2.86) for Charlson scores 1–2, 3–4 and ≥5 (ptrend<0.001),
respectively. The analysis restricted to diagnoses recorded in the
1-year period prior to the index date gave a similar magnitude of
effects (see online supplementary table S2).
All cardiovascular and genitourinary diseases were associated
with a higher risk for incident gout, the highest risk being for
renal diseases (OR, 5.96) and congestive heart disease (OR,
4.37) (see online supplementary table S2). In addition, hyperlip-
idaemia (OR 1.71), hypothyroidism (OR 1.50), anaemia (OR
1.40), psoriasis (OR 1.32), chronic pulmonary diseases (OR
1.30), osteoarthritis (OR 1.27) and depression (OR 1.09) also
positively associated with incident gout in adjusted models in
the 10-year and 1-year periods, while dementia (OR 0.54), mul-
tiple sclerosis (OR 0.61) and other neurological diseases (OR
0.83) were negatively associated with incident gout.
Interestingly, uncomplicated DM and complicated DM were not
signiﬁcant risk factors for incident gout, even showing a slight
negative association in logistic regression models.
Follow-up data after index date
Overall, median time to ﬁrst comorbidity in the Charlson index
was 43 months (95% CI 41 months to 45 months) in patients
with incident gout and 111 months (95% CI 108 months to
115 months) in controls (log-rank test p<0.001). The cumula-
tive probability of having the ﬁrst comorbidity in the Charlson
index at 1 year, 2 years, 5 years and 10 years from index date
were, respectively, 42.09%, 45.39%, 53.99% and 66.28% in
patients with incident gout and 30.78%, 33.32%, 40.92% and
51.54% in controls (ﬁgure 1A). In addition, the cumulative
probability of any increase in Charlson score was signiﬁcantly
greater in patients with gout than in controls at all time points
after diagnosis (log-rank test, p<0.001; ﬁgure 1B). Table 2
shows cumulative probabilities for speciﬁc comorbidities
(including existing and new ones) in patients with incident gout
and matched controls at index date and 1 year, 2 years, 5 years
and 10 years after index date. It is apparent that cumulative
risks of most categories of comorbidity after index date were
higher in patients with gout than in matched controls.
Next we investigated relative risk of incident comorbidity.
Among people with a Charlson score of zero at index date, gout
associated with adjusted HRs (95% CI) of 1.41 (1.34 to 1.48)
for having a Charlson index ≥1. Furthermore, risk of
Figure 1 Cumulative probability of (A) having the ﬁrst comorbidity in
the categories of Charlson index (B) an increase in the score of
Charlson index in patients with incident gout (solid line) and matched
controls (dotted line).
Table 1 Characteristics of patients with incident gout and
controls. Values are numbers (percentages) unless stated otherwise
Incident gout
(n=39 111)
Controls
(n=39 111)
Adjusted ORs
(95% CI)
Age (years)
<50 8661 (22.14) 8709 (22.27) N/A
50–59 7815 (19.98) 7822 (20.00) N/A
60–69 8586 (21.95) 8608 (22.01) N/A
≥70 14 049 (35.92) 13 972 (35.72) N/A
Gender
Men 28 350 (72.49) 28 350 (72.49) N/A
Women 10 761 (27.51) 10 761 (27.51) N/A
Median observation years (IQR)
Prior to index date 15 (9–27) 15 (9–27) N/A
After index date 9 (5–11) 9 (5–11) N/A
BMI (kg/m2)
<18.5 261 (0.67) 564 (1.44) 0.66 (0.56–0.77)*
18.5–24.9 7894 (20.18) 11 734 (30.00) Reference
25.0–29.9 15 206 (38.88) 12 815 (32.77) 1.81 (1.74–1.88)*
≥30 12 199 (31.19) 6076 (15.54) 3.15 (3.01–3.30)*
Unknown 3551 (9.08) 7922 (20.26) 0.60 (0.57–0.63)*
Smoking
Non-smoker 10 315 (26.37) 8835 (22.59) Reference
Current smoker 5783 (14.79) 4233 (10.82) 1.22 (1.16–1.29)*
Ex-smoker 18 269 (46.71) 17 136 (43.81) 0.87 (0.83–0.90)*
Unknown 4744 (12.13) 8907 (22.77) 0.39 (0.37–0.41)*
Alcohol consumption (units/week)
Never/Ex-drinker 4051 (10.36) 4338 (11.09) Reference
Current 1–9 17 410 (44.51) 17 123 (43.78) 1.14 (1.09–1.20)*
Current ≥10 10 285 (26.30) 5801 (14.83) 2.14 (2.02–2.27)*
Unknown 7365 (18.83) 11 849 (30.30) 0.63 (0.60–0.67)*
*p<0.05.
†Adjusted for age, gender and index year.
BMI, body mass index; IQR, interquartile range.
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developing incident comorbidity in the categories of cardiovas-
cular, genitourinary, metabolic/endocrine and musculoskeletal/
connective tissue diseases was higher in patients with gout (table
3). For example, patients with gout were three times more likely
to develop renal diseases (HR 3.18, 95% CI 2.88 to 3.50). In
addition, risks of liver diseases, hemiplegia, depression, anaemia
and psoriasis were also higher in patients with gout. In contrast,
patients with gout were less likely (HR 0.82, 95% CI 0.73 to
0.92) to have dementia.
After index date, mortality at 5 years and 10 years (95% CIs)
from any cause was 14.43% and 26.98% in patients with inci-
dent gout, compared with 11.14% and 21.66% in matched con-
trols (log-rank test, p<0.001; see online supplementary table
S3). In men and women estimates of the effect of a gout diagno-
sis on mortality were attenuated after adjustment for demo-
graphic and lifestyle variables (model 2), and attenuated even
further after adjustment for comorbidity status at index date
(model 3) (see online supplementary table S4). After the adjust-
ment for age, sex, index year, BMI class, smoking status, alcohol
consumption and all individual comorbidities at diagnosis
(model 3), gout associated with a HR (95% CI) for all-cause
mortality of 1.13 (1.08 to 1.18; p<0.001).
DISCUSSION
This study used a large primary care database in the UK to
compare the burden of existing comorbidity at diagnosis in
patients with gout with matched controls and to estimate the
risks of developing new comorbidities following diagnosis.
Overall, a third of patients with newly diagnosed gout already
had a Charlson score ≥1, compared with a quarter of matched
controls. The prevalence of hypertension, cardiac arrhythmias,
valvular heart disease, urolithiasis, hyperlipidaemia,
Table 2 Cumulative probability of comorbidity after diagnosis of gout
Patients with incident gout Controls
At diagnosis 1 year 2 years 5 years 10 years At diagnosis 1 year 2 years 5 years 10 years p Value
Charlson index ≥1 38.25 42.09 45.39 53.99 66.27 27.97 30.78 33.32 40.91 51.54 <0.001
Any increase in Charlson index 0 3.88 7.30 16.60 31.19 0 3.80 6.95 14.54 23.24 <0.001
Neoplasms
Solid malignancy, leukaemia and lymphoma 5.35 6.47 7.76 11.84 19.44 4.49 5.54 6.56 10.27 16.76 <0.001
Metastatic solid tumours 0.14 0.30 0.51 1.05 2.08 0.16 0.33 0.49 0.97 1.88 0.266
Cardiovascular diseases
Hypertension 34.81 38.46 41.58 49.62 59.64 18.70 21.28 23.85 30.50 39.19 <0.001
Cardiac arrhythmias 8.80 9.93 11.00 14.01 19.10 3.72 4.30 5.02 6.95 10.64 <0.001
Cerebrovascular disease 5.99 7.02 7.95 10.46 14.48 4.13 4.92 5.57 7.65 10.74 <0.001
Congestive heart failure 8.54 9.49 10.30 12.04 14.59 2.35 2.87 3.28 4.37 6.03 <0.001
Myocardial infarction 5.47 6.12 6.63 8.15 10.54 2.76 3.23 3.57 4.86 6.87 <0.001
Peripheral vascular disease 3.85 4.43 4.93 6.23 8.35 2.36 2.65 2.92 3.92 5.49 <0.001
Valvular heart disease 2.27 2.60 2.96 3.94 5.71 0.96 1.12 1.29 1.78 2.87 <0.001
Genitourinary diseases
Urolithiasis 0.94 1.05 1.14 1.42 1.99 0.66 0.73 0.82 1.07 1.42 <0.001
Renal diseases 3.05 4.20 5.30 8.50 12.51 0.54 0.76 1.07 2.22 4.04 <0.001
Metabolic and endocrine diseases
Uncomplicated diabetes mellitus 7.08 8.37 9.66 13.87 20.87 5.83 6.46 7.11 9.21 12.50 <0.001
Diabetes mellitus with complications 1.30 1.64 2.03 3.60 13.92 1.13 1.43 1.71 2.79 8.41 <0.001
Hyperlipidaemia 10.11 11.75 13.23 17.10 22.05 5.37 6.30 7.28 10.04 13.94 <0.001
Hypothyroidism 3.61 4.15 4.68 6.22 8.29 2.23 2.60 2.95 4.03 5.58 <0.001
Gastrointestinal and hepatic diseases
Peptic ulcer disease 2.02 2.33 2.54 3.10 3.88 1.78 1.96 2.11 2.50 3.14 <0.001
Mild liver disease 0.39 0.52 0.62 1.11 1.99 0.29 0.35 0.40 0.60 0.94 <0.001
Moderate to severe liver disease 0.08 0.10 0.11 0.21 0.43 0.07 0.08 0.10 0.18 0.30 0.002
Chronic pulmonary diseases 13.59 14.70 15.62 18.20 22.02 9.83 10.57 1.44 13.66 17.15 <0.001
Musculoskeletal and connective tissue diseases
Osteoarthritis 10.91 12.71 14.24 18.30 24.00 7.80 8.83 9.77 12.47 16.55 <0.001
Rheumatological disease 7.12 8.46 9.72 12.94 18.78 6.12 6.77 7.37 9.22 12.31 <0.001
Neurological and mental disorders
Dementia 0.30 0.46 0.65 1.29 2.97 0.56 0.79 1.02 1.79 3.76 <0.001
Hemiplegia 0.39 0.48 0.55 0.6 1.03 0.37 0.44 0.46 0.64 0.80 0.007
Multiple sclerosis 0.08 0.09 0.09 0.11 0.13 0.15 0.16 0.17 0.19 0.23 0.003
Other neurological diseases 1.77 2.17 2.53 3.62 5.30 2.17 2.51 2.84 3.84 5.65 0.071
Psychosis 0.40 0.49 0.55 0.75 1.16 0.24 0.61 0.68 0.93 1.27 0.234
Depression 12.10 13.60 14.97 18.90 24.74 10.39 11.45 12.59 15.76 20.59 <0.001
Other comorbidities
Anaemia 8.84 1.45 11.75 16.11 23.43 5.86 6.68 7.55 10.43 15.55 <0.001
Psoriasis 3.20 3.53 3.81 4.63 5.81 2.24 2.40 2.61 3.12 3.85 <0.001
HIV infection 0.03 0.03 0.04 0.04 – <0.001 – – 0.03 – 0.027
Figures are probability of incident comorbidity (percentage).
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hypothyroidism, chronic pulmonary disease, osteoarthritis,
depression, anaemia and psoriasis were all signiﬁcantly higher in
patients with incident gout than controls. Furthermore, approxi-
mately half of patients with gout had a Charlson index ≥1
within 5 years from initial diagnosis, whereas it took 10 years
for half the controls to develop a Charlson index ≥1. Patients
with incident gout without a prior history of these comorbid-
ities were more likely than controls to develop cancer, cardio-
vascular diseases, urolithiasis, renal diseases, DM,
hyperlipidaemia, hypothyroidism, peptic ulcer disease, mild
liver disease, osteoarthritis, rheumatological disease, depression,
anaemia and psoriasis than controls. Despite other diseases
which affect longevity, gout itself carried an additional 13% of
deaths in the affected patients. Overall, the burden of
comorbidity is very high at diagnosis of gout and the risk of
developing new comorbidity is also higher in patients with inci-
dent gout than in the general population.
The associations between gout and several categories of
comorbidities are well known. For instance, the association
between gout and the components of metabolic syndrome
is consistently reported38–40 and is explained by known
inter-relationship between these factors, in part mediated
through effects on urate production, renal angiotensin secretion
and renal urate excretion.41 42 However, the association
between gout and type 2 DM is more complex.43–45 Gout is a
risk factor for DM but the risk of DM was not increased in
patients with gout at diagnosis. Gout is a known risk factor for
cardiovascular diseases such as cerebrovascular disease,46
Table 3 Risk of incident comorbidity after diagnosis of gout
At-risk cases At-risk controls Unadjusted HRs Adjusted HRs†
All-cause mortality 39 111 (25.40) 39 111 (20.20) 1.34 (1.29–1.39)* 1.36 (1.31–1.42)*
Charlson index ≥1 24 152 (41.31) 28 171 (29.40) 1.62 (1.55–1.70)* 1.41 (1.34–1.48)*
Any increase in Charlson index 39 111 (25.51) 39 111 (21.18) 1.31 (1.26–1.36)* 1.20 (1.16–1.26)*
Neoplasms
Solid malignancy, leukaemia and lymphoma 37 040 (12.52) 37 375 (11.04) 1.17 (1.11–1.23)* 1.10 (1.04–1.16)*
Metastatic solid tumours 39 057 (1.57) 39 047 (1.47) 1.06 (0.93–1.21) 1.04 (0.91–1.20)
Cardiovascular diseases
Hypertension 25 496 (31.47) 31 798 (21.21) 1.83 (1.74–1.92)* 1.51 (1.43–1.58)*
Cardiac arrhythmias 35 669 (9.60) 37 656 (6.18) 1.74 (1.62–1.86)* 1.59 (1.48–1.70)*
Cerebrovascular disease 36 767 (7.74) 37 494 (5.99) 1.38 (1.29–1.47)* 1.29 (1.62–1.86)*
Congestive heart failure 35 772 (5.78) 38 192 (3.25) 2.01 (1.84–2.18)* 1.81 (1.65–1.98)*
Myocardial infarction 36 973 (4.39) 38 032 (3.52) 1.25 (1.14–1.37)* 1.16 (1.05–1.28)*
Peripheral vascular disease 37 605 (3.90) 38 189 (2.62) 1.58 (1.44–1.74)* 1.56 (1.40–1.72)*
Valvular heart disease 38 223 (2.93) 38 735 (1.64) 1.96 (1.76–2.19)* 1.80 (1.60–2.04)*
Genitourinary diseases
Urolithiasis 38 743 (0.84) 38 855 (0.63) 1.39 (1.16–1.67)* 1.26 (1.02–1.55)*
Renal diseases 37 919 (8.00) 38 899 (2.81) 3.43 (3.13–3.76)* 3.18 (2.88–3.50)*
Metabolic and endocrine diseases
Uncomplicated diabetes mellitus 36 342 (12.07) 36 832 (5.94) 2.15 (2.02–2.29)* 1.65 (1.54–1.77)*
Diabetes mellitus with complications 38 604 (10.82) 38 669 (6.29) 1.80 (1.70–1.92)* 1.35 (1.26–1.45)*
Hyperlipidaemia 35 156 (10.69) 37 011 (7.30) 1.64 (1.54–1.75)* 1.40 (1.31–1.50)*
Hypothyroidism 37 701 (4.00) 38 237 (2.81) 1.53 (1.40–1.68)* 1.46 (1.32–1.61)*
Gastrointestinal and hepatic diseases
Peptic ulcer disease 39 079 (0.29) 39 084 (0.19) 1.53 (1.09–2.16)* 1.37 (0.95–2.00)
Mild liver disease 38 321 (1.64) 38 416 (1.12) 1.52 (1.32–1.75)* 1.47 (1.26–1.72)*
Moderate to severe liver disease 38 960 (1.26) 38 997 (0.53) 2.39 (2.00–2.85)* 1.97 (1.61–2.41)*
Chronic pulmonary diseases 33 795 (8.11) 35 267 (6.81) 1.20 (1.12–1.28)* 1.10 (1.02–1.18)*
Musculoskeletal and connective tissue diseases
Osteoarthritis 34 843 (12.10) 36 062 (7.84) 1.71 (1.61–1.82)* 1.45 (1.35–1.54)*
Rheumatological disease 36 325 (10.43) 36 719 (5.54) 1.96 (1.84–2.10)* 1.57 (1.46–1.69)*
Neurological and mental disorders
Dementia 38 994 (2.22) 38 892 (2.63) 0.83 (0.75–0.93)* 0.82 (0.73–0.92)*
Hemiplegia 38 959 (0.51) 38 968 (0.36) 1.50 (1.19–1.89)* 1.48 (1.16–1.90)*
Multiple sclerosis 39 081 (0.05) 39 053 (0.06) 0.70 (0.37–1.30) 0.70 (0.22–2.18)
Other neurological diseases 38 419 (3.01) 38 261 (2.94) 1.08 (0.98–1.19) 1.06 (0.96–1.17)
Psychosis 38 953 (0.63) 38 901 (0.60) 1.00 (0.81–1.23) 1.04 (0.82–1.32)
Depression 34 379 (11.93) 35 047 (9.42) 1.28 (1.21–1.35)* 1.19 (1.12–1.26)*
Other comorbidities
Anaemia 35 727 (13.54) 36 854 (8.63) 1.74 (1.65–1.84)* 1.58 (1.49–1.68)*
Psoriasis 37 858 (2.17) 38 233 (1.35) 1.62 (1.44–1.82)* 1.53 (1.34–1.74)*
HIV infection 39 099 (0.02) 39 108 (0.02) 2.00 (0.60–6.64) 1.84 (0.62–5.44)
Figures are number of at-risk population (percentage of at-risk population who developed incident comorbidity) and HRs (95% CIs).
*p<0.05.†Adjusted for age, gender, index year, BMI class, smoking status and alcohol consumption.
BMI, body mass index.
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congestive heart failure47 and myocardial infarction,6 12–14 48
collectively leading to an increased risk for all-cause and cardio-
vascular mortality in patients with gout.15 49 This association
may be mediated via endothelial dysfunction caused by high
uric acid and low grade crystal-induced inﬂammation.50 Links
between hyperuricaemia and kidney disease are well-
established51–53 although convincing data for an aetiological
link between gout and chronic kidney disease are sparse.10
Although a higher risk of urolithiasis was reported half a
century ago54 55 solid evidence for this emerged only recently8 9
and studies using CT identiﬁed renal calculi in a third of
patients with gout56 suggesting underestimation of the magni-
tude of this risk in studies based solely on a history of symptom-
atic calculi.
The associations between gout and some or the other comorbid-
ities identiﬁed in this study have received less attention. An associ-
ation between gout and hypothyroidism has been suggested
previously in older case series and studies of patients not represen-
tative of the general population.18 19 57 A possible explanation for
this association is the ability of thyroid hormone to inﬂuence
serum urate levels through regulation of glomerular ﬁltration
rate.58 There is no clear explanation for the association between
gout and anaemia,20 although hyperuricaemia could result
from the increased synthesis of nucleic acids resulting from an
erythropoietic response59 and conversely greater consumption of
non-steroidal anti-inﬂammatory drugs (NSAID) for joint pain
could cause anaemia through gastrointestinal bleeding.
Co-localisation of gout and osteoarthritis has been reported
previously60 and possible explanations for this include reduced
viability of chrondrocytes61 and mechanical and inﬂammatory
effects of urate crystals on cartilage, and the heightened propen-
sity of damaged cartilage to facilitate monosodium urate crystal
nucleation.62 Gout is also associated with cancer16 17 and psor-
iasis,63 both diseases being associated with increased cell turn-
over that can cause hyperuricaemia. An association between
gout and liver disease is difﬁcult to explain, although a relation-
ship between gout and non-alcoholic fatty liver disease has been
suggested previously,64 both of which are related to insulin
resistance.
In contrast to the positive associations above, neurodegenera-
tive conditions such as dementia and multiple sclerosis seem to
have an inverse relationship with incident gout. The association
is more apparent prior to presentation with gout than during
follow-up analysis. Uric acid has antioxidant effects that particu-
larly may afford a beneﬁcial effect on central neural tissue
degeneration65 and ageing,66 though any such beneﬁt is prob-
ably largely outweighed in other tissues due to the deleterious
effects of uric acid on vascular endothelium.67 Only a few
studies have reported that lower urate associates with an ele-
vated risk of multiple sclerosis68 but our study supports this.
Such negative associations with hyperuricaemia and gout are
important in informing the debate concerning the optimum
level of urate that we should target in the long term to prevent
further crystal formation while avoiding neurological problems
from taking the level too low.69
The other associations identiﬁed in this study between gout
and other comorbidities are harder to explain. Previous case
reports have suggested that polycythaemia secondary to chronic
lung disease might contribute to gout.70 In addition, tophi have
been found in lung tissue of a patient with interstitial inﬂamma-
tion and pleural effusion.71 Patients with HIV infection seem to
have a higher risk of gout and this potentially could result from
use of antiretroviral agents such as ritonavir which may cause
lipodystrophy, metabolic disturbance and hyperuricaemia.72
The existence of comorbidity greatly complicates the manage-
ment of gout and requires special attention in managing patients
with gout. Currently, European,21 British23 and American guide-
lines22 have considered comorbidity as part of initial assessment
of patients with gout and the recommended management of
chronic hyperuricaemia also partly depends on the existence of
comorbidities. However, as our data show, comorbidities with
higher absolute and relative risks were not limited to the recom-
mended ‘checklist’. Hypothyroidism and anaemia are two exam-
ples. Yet screening for thyroid function is not mentioned in any
of the guidelines and only the American College of
Rheumatology guideline recommends a complete blood cell
count for patients with gout,22 which is mainly to look for mye-
loproliferative disease rather than anaemia. Therefore, this study
supports the case for a comprehensive investigation for
comorbidities, including but not limited to ‘checklists’, as an
integral part of initial assessment for patients with gout at diag-
nosis. Furthermore, given that half of patients with gout are
expected to have one or more comorbidities within 5 years
from diagnosis, close observation by annual assessment for the
occurrence of incident comorbidity may be warranted.
There are several limitations to this study. First, there may be
some misclassiﬁcation bias since the identiﬁcation of patients
with gout was based on physician diagnosis, rather than accord-
ing to classiﬁcation criteria73 74 or to the ‘gold standard’ of
urate crystal identiﬁcation. However, the validity of gout diag-
nosis in the CPRD has been investigated and found to be
high.32 Similarly, there may have been some misclassiﬁcation of
comorbidities though again, most of the comorbidities in this
study have been validated previously.28 In addition, there is no
reason to suspect a differential misclassiﬁcation between patients
with gout and those without. Second, differential ascertainment
bias between patients with incident gout and controls cannot be
excluded entirely, even though the estimates based on different
lengths of previous observations produced similar results. Third,
the models did not adjust for all potential risk factors for gouty
arthritis, such as diet and physical activity, both of which are
not routinely recorded in the CPRD. Fourth, the problem asso-
ciated with multiple testing may arise in our study. However,
this study aimed to provide estimates of disease burden of
patients with gout at diagnosis and subsequent to diagnosis,
rather than to deﬁne causes of gout and the main focus of this
analysis was to identify exposures and outcomes that are more
closely associated with gout. Also, most of the results were inter-
preted in the light of existing research so the conclusions are
unlikely to have been affected unduly by false-positive ﬁndings.
In addition, the sample size of this study is about 62 000
people. Even when a Bonferroni correction is applied, which is
very conservative when the multiple outcome measures under
consideration are not independent, the majority of previously
signiﬁcant results remained.
In conclusion, the majority of patients with gout in the UK
already have comorbidity at diagnosis and the risk of incident
comorbidity continues to rise after diagnosis. All-cause mortality
was higher in patients with gout and the increased risk was con-
tributed to by gout itself and by comorbidities to approximately
the same degree. This study suggests that a thorough search for
a broad range of comorbidity and subsequent vigilant observa-
tion should be considered for all patients with gout from the
date of ﬁrst diagnosis.
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